Phase II study of IC270 for allergic conjunctivitis
Latest Information Update: 04 Aug 2020
At a glance
- Drugs IC 265 (Primary) ; IC 270 (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- 04 Aug 2020 New trial record
- 08 May 2020 According to an IACTA Pharmaceuticals media release, study completion is expected in 2021.